TABLE 6.

Anticancer effects of naringin based on google patents and US patents registry.

Patent NO	Cancer types	Subjects	Results	Major outcomes	References
ES2519040T3	Liver and lung cancers	Cell lines, animals, and humans	Inhibiting TGF-β1 signaling pathway; improving serum IFN-γ	Treating or preventing fibrosis and tumors	Liang et al. (2008)
US7326734B2	Bladder cancer	Cell lines	Inhibiting cell proliferation	Treating or preventing tumors	Zi et al. (2004)
US10307393B2	Pulmonary carcinoma, esophageal carcinoma, breast carcinoma, and mediastinum tumors	Cell lines and animals	Reducing the release of the inflammatory factors (IL-1β, IL-6, TNF-α, TGF-β, and IFN-γ)	Radiotherapy protection and treating tumors	Liang et al. (2016)
JP2005508312A	Colorectal, cervical, gastric, lung cancer, malignant glioma, ovarian, and pancreatic cancers	Cell lines, animals, and humans	Inhibiting MDR1 gene expression	Treating or preventing tumors	Gunther and Reinhold, (2005)
KR20060120101A	Prostate, colorectal, and liver cancers	Cell lines	Binding to EGR-1-like promoter sequences to modulate the expression of cancer related genes (p21 and p53)	Treating or preventing tumors	Wong et al. (2004)

EGR1, early growth response 1; IFN-γ, interferon-γ; IL-1β, interleukin-1β; IL-6; interleukin-6; MDR1, multi-drug resistance-1; TGF-β1, transforming growth factor-β1; TNF-α, tumor necrosis factor-α.